AAPM has contracted with NCRP to provide each AAPM Member in good standing access and download privileges of electronically available NCRP reports, commentaries and statements. This report was prepared by the National Council on Radiation Protection and Measurements (NCRP). The Council strives to provide accurate, complete and useful information in its reports. However, neither the NCRP, the members of NCRP, other persons contributing to or assisting in the preparation of this report, nor any person acting on the behalf of any of these parties (a) makes any warranty or representation, express or implied, with respect to the accuracy, completeness or usefulness of the information contained in this report, or that the use of any information, method or process disclosed in this report may not infringe on privately owned rights; or (b) assumes any liability with respect to the use of, or for damages resulting from the use of, any information, method or process disclosed in this report.
 |
Commentary No. 011 - Dose Limits for Individuals Who Receive Exposure from Radionuclide Therapy Patients (1995)  Price: $25 PDF (AAPM Members FREE) Category: Commentary Commentary No. 11 (1995) is a result of concern about the exposure of family members of recently discharged radionuclide therapy patients. This subject was last addressed in NCRP Report No. 37 entitled, Precautions in the Management of Patients Who Have Received Therapeutic Amounts of Radionuclides, which was published in 1972. Family members of radionuclide therapy patients would usually be considered members of the public and, therefore, would normally be limited to 1 mSv annually. However, because of the infrequent nature of the exposure and because of the benefits that accrue to a family from a patient's radiation therapy. Commentary No. 11 considers it acceptable for family members of such patients to accrue up to 5 mSv annually and that there may be specific instances when the patient's physician would allow a member of the patient's family to receive an exposure of up to 50 mSv annually. In cases when such an exposure is anticipated, training and individual monitoring should be provided. In the Commentary, there is a discussion of the different types of therapy that can be provided and of the potential exposure from each therapeutic modality. Material in an appendix provides examples of the various situations that can occur. Ultimately, the material in the Commentary is to be included in the revision on NCRP Report No. 37 which is now underway. Scientific Committee: Anthony R. Benedetto, Chairman James E. Carey Harold Dworkin Richard G. Lane |
DISCLAIMER